Copanlisib
Endometrial Endometrioid Adenocarcinoma
Explore 10 assets in Endometrial Endometrioid Adenocarcinoma →Floatz Rating
CCC51/100
Confidence
Indicative
Sponsor
NRG Oncology
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
36Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02728258CT.gov Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Endometrial Endometrioid Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Copanlisib (this asset) | NRG Oncology | P2 | CCC · 51 |
| Anastrozole | Memorial Sloan Kettering Cancer Center | P2 | B |
| Nivolumab | National Cancer Institute (NCI) | P2 | CCC |
| Ipilimumab | National Cancer Institute (NCI) | P2 | CCC |
| Tazemetostat | National Cancer Institute (NCI) | P2 | CCC |
| Tirzepatide | UNC Lineberger Comprehensive Cancer Center | P2 | CCC |
| Onapristone | Memorial Sloan Kettering Cancer Center | P2 | CCC |
| Tuvusertib | National Cancer Institute (NCI) | P1 | CC |
| Atezolizumab | UNC Lineberger Comprehensive Cancer Center | P1 | CC |
+4 more in the Endometrial Endometrioid Adenocarcinoma cohort
Other indications for Copanlisib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Hodgkin Lymphoma | — | P3 | B · 61 |
| Breast Cancer | — | P2 | B · 57 |
| Breast Carcinoma | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Copanlisib in Endometrial Endometrioid Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/copanlisib-endometrial-endometrioid-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →